SLS Invest and SEB sell Sanos

The investors acquired a stake in the company following a DKK 60m investment in 2004, with SLS Invest becoming the largest shareholder. Sanos was established in 2004 as a spinout from Nordic Bioscience and focuses on the development of GLP-2 for the treatment of osteoporosis.

According to SLS Invest, the company has struggled to attract sufficient capital to take Sanos' osteoporosis drug through phase 3 clinical development. The sale gives Sanos the resources and capital necessary to complete the final phase 3 trials and bring the drug to market.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Exits
• SEB
• Denmark